Third-quarter worldwide sales of
Reported diluted EPS from continuing operations under GAAP was
Abbott projects full-year 2020 diluted EPS from continuing operations on a GAAP basis of at least
In August, Abbott received FDA Emergency Use Authorization for its BinaxNOW COVID-19
During the quarter, Abbott launched FreeStyle Libre 2 and obtained CE Mark for FreeStyle Libre 3, which automatically delivers up-to-the-minute glucose readings, unsurpassed 14-day accuracy2 and real-time glucose alarms in the world's smallest and thinnest3 wearable sensor at the same affordable price4 as previous versions. Abbott also announced CE Mark for its Libre Sense Glucose Sport Biosensor, which helps athletes better understand the efficacy of their nutritional choices on training and athletic performance.
In September, Abbott obtained CE Mark for MitraClip G4, its next-generation MitraClip heart device, the leading minimally invasive mitral valve repair device in the world.
'Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging conditions,' said
ABBOTT'S GUIDANCE FOR 2020
Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least
ABBOTT DECLARES 387TH CONSECUTIVE QUARTERLY DIVIDEND
On
Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
Contact:
Tel: 224-668-0791
(C) 2020 Electronic News Publishing, source